Framingham, MA, United States of America

Umar Faruk Mansoor

USPTO Granted Patents = 23 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 16 (Patent Applications = 14)

Average Co-Inventor Count = 9.8

ph-index = 4

Forward Citations = 65(Granted Patents)

Location History:

Farmingham, MA (US) (2009)
Framington, MA (US) (2016)
Framingham, MA (US) (2009 - 2018)
Hopkinton, MA (US) (2018 - 2024)

Company Filing History:

18 out of 2,405

Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12414952 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-09-16),

2. 12263171 - 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2025-04-01),

3. 12060357 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2024-08-13),

4. 11312719 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2022-04-26),

5. 10975084 - KDM5 inhibitors (2021-04-13),

6. 9988397 - ERK inhibitors (2018-06-05),

7. 9969749 - Inhibitors of IRAK4 activity (2018-05-15),

8. 9943516 - Inhibitors of IRAK4 activity (2018-04-17),

9. 9932350 - Inhibitors of IRAK4 activity (2018-04-03),

10. 9926330 - Inhibitors of IRAK4 activity (2018-03-27),

11. 9233979 - Compounds that are ERK inhibitors (2016-01-12),

12. 9227971 - Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors (2016-01-05),

13. 9226922 - Compounds that are ERK inhibitors (2016-01-05),

14. 9023865 - Compounds that are ERK inhibitors (2015-05-05),

15. 8999957 - Heterocyclic compounds as ERK inhibitors (2015-04-07),

Title: Innovations by Umar Faruk Mansoor: A Pioneering Inventor in Pharmaceutical Compounds

Introduction

Umar Faruk Mansoor, based in Framingham, MA, USA, is an inventor renowned for his contributions to the field of pharmaceuticals. With a remarkable portfolio of 22 patents, he has made significant advancements in the development of adenosine receptor antagonists aimed at treating various diseases.

Latest Patents

Mansoor's latest patents include innovative compounds such as 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives. These compounds, as outlined in his inventions, function as adenosine receptor antagonists, providing potential in the treatment of disorders mediated by the A2a and A2b receptors. The patents also describe pharmaceutical compositions comprising these compounds, which can be used alone or in conjunction with other therapeutic agents. Additionally, he has developed 9-substituted amino triazolo quinazoline derivatives, further enhancing the pharmaceutical landscape targeted at A2 receptor pathways.

Career Highlights

Throughout his career, Umar Faruk Mansoor has been associated with prestigious organizations such as Merck Sharp & Dohme Corporation and Schering Corporation. His work in these companies has been instrumental in bridging the gap between innovative research and practical pharmaceutical applications.

Collaborations

Mansoor has collaborated with notable coworkers, including M Arshad Siddiqui and Jongwon Lim. These collaborations have fostered a conducive environment for innovation and have significantly contributed to his successful patent portfolio.

Conclusion

Umar Faruk Mansoor continues to make strides in pharmaceuticals through his innovative creations and collaborations. His dedication to advancing the understanding and treatment of diseases through adenosine receptor antagonists represents a significant impact on medical science, with the potential for far-reaching implications in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.